Quality of Life Program: National Cultural Awards culminates support to Saudi culture, intellectuals    KSrelief Continues Distributing Ramadan Food Baskets in Lebanon    King, Crown Prince condoles Turkmen president on death of his father    Two Holy Mosques Affairs General Presidency: Increasing capacity of Mataf Courtyard, allocating 4 paths for elderly    India Reports New High of 1,761 Daily COVID-19 Deaths    Russia reports 8,164 new COVID-19 cases, 379 deaths    Custodian of the Two Holy Mosques Directs Disbursement of SR 1.9 Billion of Ramadan Aid for Social Insurance Beneficiaries    China administered total of 195.02 mln COVID-19 vaccines as of April 19    Prince Khalid meets with UK PM's envoy to Gulf region    10 million people in UK receive second dose of COVID-19 vaccine    Video clip showing expats being assaulted is old: Riyadh Police    US immigration agencies ordered to end use of terms 'alien' and 'assimilation'    US warns against travel to 80% of all countries due to COVID-19 State Department 'strongly recommends' US citizens reconsider any travel aborad    Chairman of Libyan Presidential Council Meets with Algerian Foreign Minister    In Jeel Tamooh's third edition, BCG experts, 100 world-class Saudi students come together    UAE government adopts 'blockchain' technology in authentication services    KSrelief signs two joint agreements to serve needy people in Yemen    Jadwa Investment partners with MHRSD to develop non-profit sector    Oilfields Supply Center's $570m investment in SPARK    SRC Obtains Good Ratings From Moody's, Fitch    National Center for Privatization Hosts Chinese Investors Forum    Saudi Stock Exchange Main Index Ends Trading Higher at 10,097 Points    Diriyah Gate participates in Kingdom's celebration of the World Heritage Day    Saudi Al-Hilal Defeats UAE Shabab Al-Ahli witn AFC Champions League    Saudi Al-Ahli, Qatari Al-Duhail Drew 1-1    Messi fires Barca to dominant Cup final win    Bayern moves closer to title but Flick says he's leaving    IRTI Report Showcases Sustainable Development Goals for IsDB Member States    Bayern move closer to title but Flick says he's leaving    The importance of legal specialization    Indian actor and environmentalist Vivek dies at age of 59    Alert over shortage of new drugs for 'world's most dangerous bacteria'    Helen McCrory, 'Harry Potter' and 'Peaky Blinders' star, dead at 52    New global compact aims to drive down diabetes deaths, boost insulin access    Welcome to beautiful Ramadan customs    Foundation stone laid for Jeddah Formula One circuit    Laying the Foundation Stone for Jeddah Formula One Circuit    King Salman Center for Disability Research Launches 2nd Edition of its Story Collection (Awareness)    Riyadh Light Witnesses Conclusion of External Artworks    Riyadh Light Turned the Capital into Lights' Aura    Colored Triangles Decorate Conference Building, at King Abdullah Financial Center    Vaccination does not invalidate fasting, says UAE Fatwa Council    It is high time to correct wrong concepts about women's status    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Court facilitates young woman's marriage after stripping father's guardianship    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    Senior Scholars Council Issues Decision No. 246 Regarding Attendance of Friday Prayer and Prayers at Mosques in a Case of Spread of Epidemic or Fear of its Spread    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





RDIF, Brazil's Bahia state agree to supply up to 50m doses of Sputnik V to Brazil
Published in The Saudi Gazette on 11 - 09 - 2020

The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and the State of Bahia (Brazil), through its Health Secretariat have signed a cooperation agreement to supply up to 50 million doses of the Russian vaccine Sputnik V, the world's first registered coronavirus vaccine, to Brazil.
Deliveries are expected to start in November 2020 subject to approval by Brazil's regulators with the consideration of results of post-registration trials. The agreement will also enable the parties to distribute the vaccine across Brazil in the future.
The agreement underlines that many countries recognize the importance of having a vaccine based on a human adenoviral vector platform in the coronavirus vaccine portfolio. The human adenoviral vector platform is a well-researched vaccine platform that has been proven safe over decades including through 75 international scientific publications and in more than 250 clinical trials.
On Sept. 9, RDIF and the pharmaceutical company Landsteiner Scientific announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico, which would help vaccinate 25% of the population. Deliveries are expected to start in November 2020 subject to approval by Mexico's regulators.
On Aug. 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on a human adenoviral vector platform.
Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors, and other details are available at sputnikvaccine.com
On Sept. 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine was published in The Lancet, one of the leading international medical journals. Phase I and Phase II trials demonstrated no serious adverse events and a stable immune response in 100% of participants.
Post-registration clinical trials of the Sputnik V vaccine involving 40,000 volunteers are currently ongoing. The preliminary results of these trials are expected to be published in October-November 2020.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said: "Russia is a leader in the development of vaccines against coronavirus and uses safe technologies proven over time. Sputnik V is based on a proven human adenoviral vector platform while other coronavirus vaccines use novel platforms, namely monkey adenoviral vectors or mRNA.
"The recent developments in the global pharmaceutical industry with suspended trials of an experimental coronavirus vaccine show the importance of a diversified approach to vaccine supplies. The signings of agreements to supply Sputnik V internationally demonstrate many countries recognize that human adenovirus-based vaccines are an absolute must-have for their national drug portfolio, as this platform has proven safe and effective over decades.
"Clinical trials of the Russian vaccine have shown no serious adverse events, with Sputnik V generating a stable humoral and cellular immune response in 100% of participants in the clinical trials. In contrast, vaccines based on novel platforms have yet to prove their safety and currently have no data on carcinogenicity or effects on fertility. We are pleased to make such an important contribution in the fight against the pandemic through providing the safe and effective Sputnik V vaccine to our partners in Brazil."
Aleksandr Rumyantsev, president of Dmitry Rogachev National Research Center, Russian Academy of Sciences academician, Doctor of Medical Sciences, professor, said: "Unlike many innovative foreign technologies, the Russian-produced vaccine differs favorably in terms of using a human adenovirus platform that has been tested over time, has proven to be sound, and whose history covers dozens of years of study and use.
"And this is the key moment when the issue arises of what to select: either a carrier that has been successfully used for a long time, and proven its worth, or a new technology (for example, a monkey adenovirus) that requires making exhaustive observations of those that have been vaccinated, and then waiting for it to stand the test of time."
Dr. Fabio Vilas-Boas Pinto, health secretary of the State of Bahia, said: "The government of the State of Bahia, in Brazil, is very pleased with the agreement signed with the Sovereign Wealth Fund of the Russian Federation, which will guarantee access to the Sputnik V vaccine for the Brazilian people, as soon as it is approved by the Brazilian national regulatory authorities.
"As it is a vaccine built using human adenovirus, which is one of the safest and most effective vaccine development platforms in the world, we believe that the results of the ongoing phase 3 clinical trials will confirm the data observed in phases 1 and 2." — PRNewswire


Clic here to read the story from its source.